DDInter1010 DDInter899
Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution. It's analgesic properties make it a useful pain management tool across many settings including postoperative pain, rheumatoid arthritis, osteoarthritis, menstrual disorders, headaches, spinal and soft tissue pain, and ankylosing spondylitis. Impressively, ketorolac has a similar efficacy to standard doses of morphine and meperidine making it a useful opioid sparing agent.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Ketorolac {u} (Compound) resembles {v} (Compound) Fenbufen
Ketorolac {u} (Compound) resembles {v} (Compound) Oxybenzone
Ketorolac {u} (Compound) binds {v} (Gene) PTGS1
Ketorolac {u} (Compound) upregulates {v} (Gene) FAIM
Ketorolac {u} (Compound) is included by {v} (Pharmacologic Class) Nonsteroidal Anti-inflammatory Compounds
Ketorolac {u} (Compound) downregulates {v} (Gene) RPS4Y1
Ketorolac {u} (Compound) causes {v} (Side Effect) Back pain
Ketorolac {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Ketorolac {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trastuzumab emtansine
Ketorolac {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anistreplase
Ketorolac (Compound) resembles Fenbufen (Compound)
Ketorolac (Compound) resembles Oxybenzone (Compound)
Ketorolac (Compound) binds PTGS1 (Gene)
Ketorolac (Compound) upregulates FAIM (Gene)
Ketorolac (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class)
Ketorolac (Compound) downregulates RPS4Y1 (Gene)
Ketorolac (Compound) causes Back pain (Side Effect)
Ketorolac may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Anistreplase